- Conditions
- Non-transfusion Dependent Thalassemia
- Interventions
- deferasirox, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Oakland, California • Chicago, Illinois • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Renal Anemia
- Interventions
- AND017, Placebo
- Drug
- Lead sponsor
- Kind Pharmaceuticals LLC
- Industry
- Eligibility
- 20 Years to 74 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Northridge, California • Winter Park, Florida • Shreveport, Louisiana + 4 more
- Conditions
- Opioid-Related Disorders, Stimulant-Related Disorder, Child Neglect, Mental Health Impairment
- Interventions
- Prevention Adaptation of Families Actively Improving Relationships (PRE-FAIR), Standard Case Management and Referral
- Behavioral
- Lead sponsor
- Chestnut Health Systems
- Other
- Eligibility
- 16 Years to 30 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Parkinson's Disease (PD)
- Interventions
- Summit RC+S
- Device
- Lead sponsor
- Doris Wang, MD, PhD
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Substance-Related Disorders
- Interventions
- Palonosetron, Hydroxyzine, Placebo
- Drug · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Metastatic Non-Small Cell Lung Cancer, NSCLC, Lung Cancer
- Interventions
- Trilaciclib, Placebo, Docetaxel
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Rancho Mirage, California + 9 more
- Conditions
- Fibromyalgia, Central Neuropathic Pain
- Interventions
- Nitrous oxide gas for inhalation, Placebo
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obesity
- Interventions
- Ribupatide, Placebo
- Drug
- Lead sponsor
- Kailera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 35
- States / cities
- Mesa, Arizona • Sun City West, Arizona • Irvine, California + 31 more
- Conditions
- Binge Eating, Pediatric Obesity
- Interventions
- Observational
- Other
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 30 participants
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Uveal Melanoma
- Interventions
- Selumetinib, 100mg, Selumetinib, 125mg, Selumetinib, 150mg, Selumetinib, 175mg, Selumetinib, 200mg, Selumetinib, 225mg
- Drug
- Lead sponsor
- Shaheer A. Khan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Smoking, Smoking Cessation, HIV Infections
- Interventions
- Nicotine Replacement Therapy, Mindfulness Training Smoking Cessation Intervention, Contingency Management Smoking Cessation Intervention
- Drug · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
- Interventions
- Allogeneic NK Cells
- Drug
- Lead sponsor
- Artiva Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 31
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
- Conditions
- Primary Progressive Aphasia
- Interventions
- high-definition transcranial direct current stimulation, modified constraint-induced language therapy
- Device · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Autism Spectrum Disorder
- Interventions
- Reciprocal Intervention Teaching (RIT), Daily Routines
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Months to 80 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum
- Interventions
- INZ-701
- Drug
- Lead sponsor
- Inozyme Pharma
- Industry
- Eligibility
- Up to 1 Year
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- San Diego, California • Columbus, Ohio • Philadelphia, Pennsylvania
- Conditions
- Glioblastoma Multiforme, Gliosarcoma
- Interventions
- Avastin, Temozolomide, Irinotecan
- Drug
- Lead sponsor
- Katy Peters
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- MRI Scans, Magnetic Resonance Imaging, Pacemaker, Implantable Cardioverter Defibrillator
- Interventions
- MRI Scan
- Other
- Lead sponsor
- Lancaster General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Spasticity With Multiple Sclerosis
- Interventions
- Nabiximols, Placebo
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more
- Conditions
- Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
- Interventions
- DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod
- Biological · Drug
- Lead sponsor
- David Bartlett
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cannabis Use
- Interventions
- Cannabis use abstinence for 11 weeks
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Stroke
- Interventions
- Overground Visual Biofeeback
- Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Lung Non-Small Cell Carcinoma
- Interventions
- Blood Oxygen Level Dependent Imaging, Papaverine Hydrochloride, Stereotactic Body Radiation Therapy
- Procedure · Drug · Radiation
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Latent Tuberculosis
- Interventions
- Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Opioid-Related Disorders, Substance-Related Disorders
- Interventions
- Buprenorphine
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 21 Years to 45 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 1998
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio